The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP). Methods: A Markov model was developed to estimate the cost effectiveness of the three TPO-RAs in adults with insufficient response to...
Sparad:
| Huvudupphov: | , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
MDPI AG
2025-03-01
|
| Serie: | Journal of Market Access & Health Policy |
| Ämnen: | |
| Länkar: | https://www.mdpi.com/2001-6689/13/2/11 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|